OTCMKTS:NSPX - Inspyr Therapeutics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.01
▼ -0.0002 (-2.50%)

This chart shows the closing price for NSPX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Inspyr Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NSPX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NSPX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Inspyr Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.01.

This chart shows the closing price for NSPX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Inspyr Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/21/2017Rodman & RenshawReiterated RatingBuy$2.00
(Data available from 6/21/2016 forward)

Inspyr Therapeutics

Inspyr Therapeutics, Inc., a pharmaceutical company, focuses on the research and development of therapeutics for the treatment of cancer. Its immune-oncology lead asset is RT-AR001, an adenosine A2B receptor antagonist for tumor infiltration. The company was formerly known as GenSpera Inc. and changed its name to Inspyr Therapeutics, Inc. in August 2016. Inspyr Therapeutics, Inc. was incorporated in 2003 and is based in Westlake Village, California.
Read More

Today's Range

Now: $0.01
Low: $0.01
High: $0.01

50 Day Range

MA: $0.01
Low: $0.01
High: $0.02

52 Week Range

Now: $0.01
Low: $0.00
High: $0.70

Volume

659,300 shs

Average Volume

12,204,446 shs

Market Capitalization

$4.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Inspyr Therapeutics?

The following sell-side analysts have issued research reports on Inspyr Therapeutics in the last twelve months:
View the latest analyst ratings for NSPX.

What is the current price target for Inspyr Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Inspyr Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Inspyr Therapeutics in the next year.
View the latest price targets for NSPX.

What is the current consensus analyst rating for Inspyr Therapeutics?

Inspyr Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for NSPX.

What other companies compete with Inspyr Therapeutics?

How do I contact Inspyr Therapeutics' investor relations team?

Inspyr Therapeutics' physical mailing address is 31200 VIA COLINAS SUITE 200, WESTLAKE VILLAGE CA, 91362. The company's listed phone number is 818-661-6302 and its investor relations email address is [email protected] The official website for Inspyr Therapeutics is www.genspera.com.